Pronunciation: ta-MOX-i-fen SI-trate
- Tablets, oral 10 mg
- Tablets, oral 20 mg
A nonsteroidal agent with antiestrogenic properties.
Tamoxifen C max is 40 ng/mL (range, 35 to 45 ng/mL), T max is approximately 5 h after dosing, and steady state is achieved in approximately 4 wk. N-desmethyl tamoxifen C max is 15 ng/mL (range, 10 to 20 ng/mL). Steady state is achieved in approximately 8 wk.
Tamoxifen is extensively metabolized. The major metabolite is N-desmethyl tamoxifen with biological activity similar to tamoxifen. It is a substrate of CYP-450 3A, 2C9, 2D6, and an inhibitor of P-glycoprotein.
Tamoxifen half-life is 5 to 7 days; 65% of a dose is excreted over a 2-wk period, with fecal excretion as the primary route of elimination. N-desmethyl tamoxifen half-life is approximately 14 days.
Special PopulationsHepatic Function Impairment
The effects of reduced liver function have not been determined.Elderly
The effects of age on the pharmacokinetics of tamoxifen have not been determined.Children
In pediatric patients, an average steady-state C max and AUC were 187 ng/mL and 4,110 ng•h/mL, respectively, and steady-state C max occurred approximately 8 h after dosing. Cl/F as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients. In the youngest cohort of female pediatric patients (2 to 6 y of age), Cl/F was 2.6-fold higher; in the oldest cohort (7 to 10.9 y of age), Cl/F was approximately 1.9-fold higher.Gender
The effects of gender on the pharmacokinetics of tamoxifen have not been determined.Race
The effects of race on the pharmacokinetics of tamoxifen have not been determined.
Indications and Usage
For the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation to reduce the risk of invasive breast cancer; treatment of metastatic breast cancer in women and men; to reduce the incidence of breast cancer in women at high risk of breast cancer.
Ovulation stimulation in specially selected anovulatory women desiring pregnancy; management and treatment of some types of mastalgia (eg, cyclical); malignant carcinoid tumor and carcinoid syndrome; migraine associated with menstruation; oligozoospermia; McCune-Albright syndrome in female pediatric patients (in combination with other agents); metastatic melanoma; desmoid tumors; gynecomastia.
Hypersensitivity to drug; women who require concomitant coumarin-type anticoagulant therapy or women with a history of deep vein thrombosis (DVT) or pulmonary embolus (PE) (reduction of breast cancer incidence in high-risk women/DCIS only).
Dosage and AdministrationBreast Cancer
PO 20 to 40 mg daily for 5 y.Ductal Carcinoma In Situ, Reduction in Breast Cancer Incidence in High-Risk Women
PO 20 mg daily for 5 y.
- Divide dosages greater than 20 mg/day (morning and evening).
Store between 68° and 77°F. Protect from light.
Tamoxifen concentrations may be reduced. Coadministration is not recommended.Anastrozole
Plasma concentrations of anastrozole may be decreased. Do not coadminister.Bromocriptine
Tamoxifen concentrations may be increased. An addition, bromocriptine GI adverse reactions (eg, abdominal pain) may be increased. Avoid coadministration if serious bromocriptine adverse reactions occur.Cation exchange resins (eg, sodium polystyrene sulfonate)
Coadministration of cation exchange resins and tamoxifen may cause serious GI adverse events such as colonic necrosis. Coadministration is not recommended.CYP2D6 inhibitors (eg, bupropion, paroxetine)
Pharmacologic effects of tamoxifen may be decreased, increasing the risk of breast cancer recurrence. Inhibition of CYP2D6 may decrease the formation of endoxifen, an active metabolite of tamoxifen. Avoid coadministration.Cytotoxic agents
Increased risk of thromboembolic events.Letrozole
Plasma concentrations may be decreased by tamoxifen, reducing the therapeutic effect. Close clinical and laboratory monitoring for signs of reduced antitumor effects of letrozole is warranted.Medroxyprogesterone
Medroxyprogesterone reduces plasma concentrations of N-desmethyl tamoxifen (metabolite) but not tamoxifen.Mitomycin C
Toxic effects of mitomycin C and tamoxifen may be increased. Anemia, thrombocytopenia, and hemolytic uremic syndrome may develop. If coadministration cannot be avoided, closely monitor the clinical and hematologic status of the patient.Phenobarbital
One patient receiving tamoxifen with concomitant phenobarbital exhibited steady-state serum concentrations of tamoxifen lower than that observed for other patients. The clinical relevance of this is unknown.Rifamycins (eg, rifampin)
Tamoxifen plasma levels may be reduced, decreasing the antiestrogenic effect. It may be necessary to increase the tamoxifen dose during coadministration. In addition, concentrations of the active metabolite of tamoxifen, endoxifen, may be elevated, increasing the risk of adverse reactions. Monitor for adverse reactions.Warfarin
Increased hypoprothrombinemic effect. Carefully monitor anticoagulant activity.
Laboratory Test Interactions
Thyroxine elevations. Variations in the karyopyknotic index on vaginal smears and various degrees of estrogen effect on Papanicolaou tests.
Vasodilation (41%); hypertension (11%); venous thromboembolic events (5%); ischemic cerebrovascular events (3%); angina pectoris, DVT events (2%); MI, PE (1%).
Asthenia/fatigue, mood disturbances (18%); depression (12%); insomnia (9%); dizziness, headache (8%); anxiety (6%); paresthesia (5%); fatigue (4%).
Flushing (33%); skin changes (19%); rash (13%); sweating (6%); alopecia (5%); bullous pemphigoid, erythema multiforme, Stevens-Johnson syndrome (postmarketing).
Pharyngitis (14%); cataract (7%).
Nausea (26%); vomiting (12%); constipation (8%); diarrhea (7%); dyspepsia (6%); GI disorder (5%); anorexia (1%).
Vaginal discharge (55%); irregular menses (25%); vaginal bleeding (23%); amenorrhea (16%); UTI (10%); leukorrhea, oligomenorrhea (9%); breast pain, menstrual disorder, vaginal hemorrhage (6%); breast neoplasm, vaginitis, vulvovaginitis (5%); ovarian cysts (3%), endometrial cancer (1%); loss of libido/impotence in men.
Lymphedema (11%); thrombocytopenia (10%); anemia (5%).
Increased AST (5%); increased bilirubin, increased creatinine (2%); elevated luteinizing hormone, follicle-stimulating hormone, estrogen, and testosterone in men; elevated triglycerides in some cases with pancreatitis (postmarketing).
Fluid retention (32%); weight loss (23%); peripheral edema (11%); weight gain (9%); hypercholesterolemia (4%).
Musculoskeletal events (29%); arthritis (14%); arthralgia (11%); back pain (10%); fracture, osteoporosis (7%); bone pain (6%); arthrosis, joint disorder, myalgia (5%); musculoskeletal pain (3%).
Cough (9%); dyspnea (8%); bronchitis, sinusitis (5%); interstitial pneumonitis (postmarketing).
Hot flashes (80%); pain (16%); accidental injury (10%); abdominal pain, infection (9%); flu syndrome, infection/sepsis (6%); chest pain, cyst, neoplasm (5%); edema (4%); abdominal cramps (1%); hypersensitivity, including angioedema (postmarketing).
Serious and life-threatening events associated with tamoxifen in the risk-reduction setting (women at high risk of cancer and women with DCIS) include uterine malignancies, stroke, and PE. Uterine malignancies consist of both endometrial adenocarcinoma and uterine sarcoma. Some of the strokes, PE, and uterine malignancies were fatal. Discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and with women with DCIS considering tamoxifen to reduce their risks of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.
Perform gynecological examinations annually. Obtain periodic CBC, including platelet counts, and periodic LFTs. Periodic monitoring of plasma triglycerides and cholesterol may be indicated in patients with preexisting hyperlipidemias.
Category D . Tamoxifen may cause fetal harm when administered to a pregnant woman. Advise women not to become pregnant while taking or within 2 mo of discontinuing tamoxifen and to use barrier or nonhormonal contraceptive measures if sexually active. Tamoxifen does not cause infertility, even in the presence of menstrual irregularity. Effects on reproductive functions are expected from the antiestrogenic properties of the drug.
Undetermined. Women taking tamoxifen should not breast-feed.
Safety and efficacy have not been established.
Thrombocytopenia, leukopenia, and neutropenia and/or pancytopenia have occurred.
Liver cancer, changes in liver enzyme levels, fatty liver, cholestasis, hepatitis, and hepatic necrosis have occurred. A few of these serious cases included fatalities.
Hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment.
Nonmalignant uterine effects
An increased incidence of endometrial changes, including hyperplasia and polyps, have been reported. Endometriosis, uterine fibroids, ovarian cysts, menstrual irregularity, and amenorrhea have been reported.
Ocular disturbances, including corneal changes, decrement in color perception, retinal vein thrombosis, and retinopathy, have been reported. An increased incidence of cataracts and the need for cataract surgery have been reported.
Convulsions, neurotoxicity, QT interval changes.
- Advise patients to review the Medication Guide before using the first time and with each refill.
- Advise patients that tamoxifen reduces the incidence of breast cancer but may not eliminate risk. Instruct patients on the benefits of tamoxifen versus the risk.
- Women with DCIS treated with lumpectomy and radiation therapy who are considering tamoxifen to reduce the incidence of a second breast cancer event should assess the risks and benefits of therapy because treatment with tamoxifen decreased the incidence of invasive breast cancer but has not been shown to affect survival.
- Advise women who are receiving or who have previously received tamoxifen to have regular gynecologic examinations and promptly inform their health care provider of menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.
- Women who are pregnant or who plan to become pregnant should not take tamoxifen to reduce the risk of breast cancer. Effective nonhormonal contraception must be used by all premenopausal women taking tamoxifen and for approximately 2 mo after discontinuing therapy if they are sexually active. Tamoxifen does not cause infertility, even in the presence of menstrual irregularity. For sexually active women of childbearing potential, initiate therapy during menstruation. In women with menstrual irregularity, a negative beta chorionic gonadotropin immediately prior to the initiation of therapy is sufficient.
- Advise patients to notify their health care provider of pain/swelling/tenderness of legs, unexplained shortness of breath, changes in vision, new breast lumps, vaginal bleeding, or gynecologic symptoms (eg, menstrual irregularities, changes in vaginal discharge, pelvic pain or pressure).
Copyright © 2009 Wolters Kluwer Health.
More Tamoxifen Citrate resources
- Tamoxifen Citrate Monograph (AHFS DI)
- Tamoxifen Prescribing Information (FDA)
- Nolvadex Prescribing Information (FDA)
- Nolvadex MedFacts Consumer Leaflet (Wolters Kluwer)
- Nolvadex Advanced Consumer (Micromedex) - Includes Dosage Information
- Soltamox Prescribing Information (FDA)
- Soltamox Concise Consumer Information (Cerner Multum)
- Soltamox solution MedFacts Consumer Leaflet (Wolters Kluwer)